ArticleProceedings of the National Academy of Sciences of the United States of America2015

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

John E Janik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.